KNG1 antibody (AA 2-110) (FITC)
Quick Overview for KNG1 antibody (AA 2-110) (FITC) (ABIN7178919)
Target
See all KNG1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 2-110
-
Cross-Reactivity
- Rat
-
Purification
- >95%, Protein G purified
-
Immunogen
- Recombinant Rat Kininogen-1 protein (2-110AA)
-
Isotype
- IgG
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 -
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C,-80 °C
-
Storage Comment
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- KNG1 (Kininogen 1 (KNG1))
-
Alternative Name
- Kng1
-
Background
-
Background: Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action), (5) LMW-kininogen inhibits the aggregation of thrombocytes, (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Aliases: Kng1 antibody, Kng antibody, Kininogen-1 [Cleaved into: Kininogen-1 heavy chain, Bradykinin, Kininogen-1 light chain] antibody
-
UniProt
- P08934
-
Pathways
- ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process
Target
-